期刊
VIRUSES-BASEL
卷 6, 期 10, 页码 3809-3826出版社
MDPI
DOI: 10.3390/v6103809
关键词
influenza; vaccines; live-attenuated virus; adjuvants; correlates of protection
类别
资金
- Ghent University Special Research Fund [BOF13/PDO/099]
- Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen
- Belgian American Educational Foundation (BAEF)
- NIAID grants [U19AI106754, U01AI095611, U19AI089987, P01AI097092]
- NIAID contracts [HHSN272201000054C, HHSN272201300023C]
- DHS [2010-ST-061-AG001]
- CRIP (Center for Research on Influenza Pathogenesis) an NIAID [HHSN272201400008C]
Vaccination is by far the most effective way of preventing morbidity and mortality due to infection of the upper respiratory tract by influenza virus. Current vaccines require yearly vaccine updates as the influenza virus can escape vaccine-induced humoral immunity due to the antigenic variability of its surface antigens. In case of a pandemic, new vaccines become available too late with current vaccine practices. New technologies that allow faster production of vaccine seed strains in combination with alternative production platforms and vaccine formulations may shorten the time gap between emergence of a new influenza virus and a vaccine becoming available. Adjuvants may allow antigen-sparing, allowing more people to be vaccinated with current vaccine production capacity. Adjuvants and universal vaccines can target immune responses to more conserved influenza epitopes, which eventually will result in broader protection for a longer time. In addition, further immunological studies are needed to gain insights in the immune features that contribute to protection from influenza-related disease and mortality, allowing redefinition of correlates of protection beyond virus neutralization in vitro.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据